Searching…
Medytox, a global biopharmaceutical company, is at the forefront of efforts to build a better future with ceaseless R&D. Since the launch of botulinum toxin type A Meditoxin® in 2006 (trade name: Neuronox®, Siax®, Bot...
Jan 3, 2024 · Established in 2000 and headquartered in South Korea, Medytox is the original Korean manufacturer of Botulinum toxin type A and the world's first company to introduce a liquid ready-to-use...
May 12, 2025 · Medytox, a Korean biopharmaceutical company specializing in botulinum toxin therapies, said it achieved consolidated revenue of 64 billion won ($45.6 million) in the first quarter of 2025, marking a 17 ...
Jun 30, 2025 · Medytox developed Meditoxin, a botulinum toxin product that has received regulatory approval in over 30 countries. However, as of mid-2025, Meditoxin remains unapproved by the FDA.
World-class research facilities and state-of-the-art manufacturing plants demonstrate the Medytox commitment to innovation, scientific excellence, and product quality. Luvantas is seeking approval for the upcoming int...
All of Medytox starts from R&D. Pipeline R&D is a starting point of drug development, commercialization and a locomotive in realizing continuous growth.
Medytox was founded in 2000 and is a global biopharmaceutical company leading the development of botulinum toxin and hyaluronic acid fillers.
Jul 1, 2025 · Medytox Inc., founded in 2000 in Seongnam, South Korea, has evolved into a prominent player in the global biopharmaceutical industry. The company specializes in neuromodulators, including Meditoxin and Innotox.
Medytox Inc. is one of the biggest manufacturer of cosmetological products from South Korea, that manages three plants in Korea and has RepOffices in seven countries. The major attention of the company is devoted to t...
Korean biopharmaceutical company Medytox is best known for pioneering Neuronox, a botulinum toxin type A (BTX-A)-based product indicated for both aesthetic and medical uses as a treatment for muscle spasticity.
